Original Article
Year : 2018 | Volume : 2 | Issue : 1 | Page : 6 - 11
Analysis of molecular markers in glioblastoma and correlation with survival pattern
Ishita Pant, Sujata Chaturvedi, Vaishali Suri1, Ajay Kumar Bansal2, Deepak Kumar Jha3,Vinod Kumar Singh Gautam3
Departments of Pathology and 3 Neurosurgery, Institute of Human Behaviour and Allied Sciences, 1 Department of Pathology, All India Institute of Medical Sciences, 2 Department of Social and Preventive Medicine, University College of Medical Sciences, New Delhi, India
Address for correspondence:
Dr. Ishita Pant, Department of Pathology, Institute of Human Behaviour and Allied Sciences, Dilshad Garden, New Delhi ‐ 110 095, India.
E‐mail: ishitapant@gmail.com
Abstract
Objective:
The objective of this study was to apply the newly recommended mandatory immunohistochemical (IHC) markers, isocitrate dehydrogenase (IDH) and ATRX, in addition to our previously applied panel of p53, epidermal growth factor receptor [EGFR], vascular endothelial growth factor [VEGF], MDM2, and Ki67 on histopathologically diagnosed thirty cases of glioblastoma. Their interrelationship and correlation with survival pattern were analyzed.
Materials and Methods:
A retrospective analysis of the histopathology records and clinical case files was done in thirty cases of glioblastoma (World Health Organization Grade IV). These cases were analyzed for certain defined clinical and histopathological parameters. IHC staining for IDH1‐R132H and ATRX was done. IHC scores for p53, EGFR, VEGF, MDM2, and Ki67 were included from the previously published dataset. IHC labeling of all these markers was analyzed, and their interrelationship was studied and correlated with the survival pattern.
Results:
Cases were categorized as glioblastoma, IDH‐wild type; glioblastoma, IDH‐mutant; and glioblastoma, not otherwise specified (NOS). A total of 17 cases were categorized as glioblastoma, IDH‐wild type and 10 cases were categorized as glioblastoma, IDH‐mutant. Three cases in younger adults were categorized as glioblastoma, NOS. In glioblastoma, IDH‐wild type, p53 expression was found in 7 cases, increased Ki67 expression was present in 12 cases, VEGF expression was found in 16 cases, MDM2 was expressed in 14 cases, while EGFR expression was present in 10 cases. In glioblastoma, IDH‐mutant, p53 expression was found in 5 cases, increased Ki67 expression was present in 4 cases, VEGF expression was found in 9 cases, MDM2 was expressed in 5 cases, while EGFR expression was present in 3 cases. The mean overall survival in glioblastoma, IDH‐wild type was 3.1 months and, in glioblastoma, IDH‐mutant, the mean overall survival was 6.4 months.
Conclusion:
Survival pattern of glioblastoma, IDH‐mutant, was better than glioblastoma, IDH‐wild type.
Keywords: ATRX, glioblastoma, isocitrate dehydrogenase, molecular markers, survival
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
How to cite this article:
Pant I, Chaturvedi S, Suri V, Bansal AK, Jha DK, Gautam VK. Analysis of molecular markers in glioblastoma and correlation with survival pattern. Int J Clinicopathol Correl 2018;2:6-11.
